Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 3/20 | 0.62 |
| ▸ | PLAU | P00749 | 3/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.54 |
| ▸ | TSLP | Q969D9 | 6/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 3/20 | 0.50 |
| ▸ | MC5R | P33032 | 3/20 | 0.50 |
| ▸ | MC3R | P41968 | 3/20 | 0.50 |
| ▸ | MC1R | Q01726 | 3/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319649 | 0.94 | CTSG (0.69) | CTSGPLAUKLKB1TSLP | |
| SCHEMBL14029285 | 0.86 | PLAU (0.57) | CTSGPLAUKLKB1TSLPALB | |
| SCHEMBL14096800 | 0.84 | CTSG (0.65) | CTSGPLAUKLKB1ALBMC4R | |
| SCHEMBL12146083 | 0.84 | TSLP (0.56) | CTSGPLAUTSLPMC4RMC5R | |
| SCHEMBL14096793 | 0.84 | CTSG (0.65) | CTSGPLAUKLKB1ALBMC4R | |
| SCHEMBL13659870 | 0.83 | CTSG (0.59) | CTSGPLAUKLKB1TSLPMC4R | |
| SCHEMBL14096946 | 0.82 | MC4R (0.59) | CTSGPLAUKLKB1TSLPMC4R | |
| SCHEMBL14096826 | 0.82 | CTSG (0.59) | CTSGPLAUKLKB1TSLPMC4R | |
| SCHEMBL13881404 | 0.81 | MC4R (0.51) | CTSGPLAUTSLPMC4RMC5R | |
| SCHEMBL13038608 | 0.81 | MC4R (0.51) | CTSGPLAUTSLPMC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137206-A1 | NOVEL LIGAND GUIDED BLOCK COPOLYMERS FOR TARGETED DRUG DELIVERY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137206-A1 | NOVEL LIGAND GUIDED BLOCK COPOLYMERS FOR TARGETED DRUG DELIVERY | EBPL, EDNRB, BMPR1B | CTSG 2061/4885PLAU 377/4885KLKB1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.